RxDoctor Payments Data

Beverly Deliz-Tirado, MD

Nephrology · Zephyrhills, FLNPI 1134314719

Payments from drug & device makers

$4,856in general payments, 2019–2025

Across 199 payments — averaging $24.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Bayer$624
  • Otsuka America Pharmaceutical, Inc.$430
  • Amgen$357
  • Calliditas Therapeutics US Inc.$225
  • OPKO Pharmaceuticals, LLC$214
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,65296%
  • Education$2044%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,856 in reported general payments places this provider in the 70th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$137,620
Medicare patients
314
Services billed
1,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin158$165,004
FarxigaDapagliflozin Propanediol81$99,091
VelphoroSucroferric Oxyhydroxide22$40,276
VeltassaPatiromer Calcium Sorbitex24$34,358
RayaldeeCalcifediol16$19,071
KerendiaFinerenone13$16,740
LokelmaSodium Zirconium Cyclosilicate18$15,985
Envarsus XrTacrolimus14$13,388
Sevelamer Carbonate59$8,666
Telmisartan178$6,013
Nifedipine ErNifedipine94$3,174
Calcitriol157$2,306
Bumetanide53$1,419
Potassium Chloride61$1,311
Hydralazine Hcl89$1,176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$174$165,004158 claims
AstraZenecaFarxiga, Lokelma$1,069$115,07699 claims
Fresenius USA Marketing, Inc.Velphoro$96$40,27622 claims
OPKO Pharmaceuticals, LLCRayaldee$214$19,07116 claims
BayerKerendia$624$16,74013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 756 nephrology providers in Florida.

Other nephrology in Zephyrhills

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →